An Open Randomised Phase II Study Of Gemcitabine Plus Cisplatin +/- Concomitant or Sequential ZD1839 in Patients With Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006903/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of the study is to assess the activity of ZD1839 250 mg once daily in
addition to the standard chemotherapy in patients with advanced or metastatic transitional
cell carcinoma of the urothelium by estimating the time to progression.
提供机构：
Vivli
创建时间：
2021-04-16
